Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Sarcoma
•
Medical Oncology
How do you treat recurrent dedifferentiated liposarcoma after initial complete resection if the recurrence is multifocal but surgically resectable?
Do you proceed to resection or palliative chemotherapy?
Related Questions
How would you manage an epidural spinal metastasis causing cord compression from rhabdomyosarcoma?
Which patient characteristics or clinical factors guide the decision to use Doxorubicin and Trabectedin as first-line treatment for metastatic or unresectable leiomyosarcoma?
How would you approach adjuvant treatment in a patient with completely resected undifferentiated pleomorphic sarcoma of the chest wall that recurred after 2 years, initially treated with neoadjuvant radiation and resection?
What factors do you consider when choosing between vimseltinib and pexidartinib for tenosynovial giant cell tumor (TGCT) patients?
How would you treat a primary angiosarcoma arising in the skull, excised with initial excisional biopsy?
What is the recommended approach for a 7 cm x 5 cm paraspinal subcutaneous desmoid tumor (T6 to T9) incidentally detected on PET CT during NSCLC monitoring, with confirmed growth over 18 months?
How do you approach an otherwise healthy patient with an incidental 1 mm GIST involving the serosal surface in terms of staging workup, EGD, and surveillance?
What is the preferred systemic therapy regimen for a patient in their 40s with untreated metastatic sarcomatoid carcinoma of unknown primary, presenting with hepatic lesions, abdominal lymphadenopathy, and a lytic bone lesion?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?